• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Bortezomib and low dose venetoclax therapy for relapsed/refractory B-cell acute lymphoblastic leukemia with IDH1 mutation.

作者信息

Borah Pronamee, Maitri Ayoniza, Naithani Rahul

机构信息

Paras Health, Gurugram, India.

Jawaharlal Nehru Medical College and Hospiatal, Bhagalpur, India.

出版信息

Hematol Transfus Cell Ther. 2024 Dec;46 Suppl 6(Suppl 6):S435-S437. doi: 10.1016/j.htct.2024.04.131. Epub 2024 Sep 20.

DOI:10.1016/j.htct.2024.04.131
PMID:39332936
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11726101/
Abstract
摘要

相似文献

1
Bortezomib and low dose venetoclax therapy for relapsed/refractory B-cell acute lymphoblastic leukemia with IDH1 mutation.硼替佐米与低剂量维奈克拉联合治疗伴有异柠檬酸脱氢酶1（IDH1）突变的复发/难治性B细胞急性淋巴细胞白血病
Hematol Transfus Cell Ther. 2024 Dec;46 Suppl 6(Suppl 6):S435-S437. doi: 10.1016/j.htct.2024.04.131. Epub 2024 Sep 20.
2
Low-dose venetoclax, bortezomib, inotuzumab, rituximab, and dexamethasone (LoVe-BIRD) in a child with relapsed/refractory B-cell acute lymphoblastic leukemia with TP53 mutation.低剂量维奈克拉、硼替佐米、伊奈妥单抗、利妥昔单抗和地塞米松（LoVe-BIRD方案）用于一名复发/难治性伴有TP53突变的B细胞急性淋巴细胞白血病儿童。
Pediatr Blood Cancer. 2024 Sep;71(9):e31152. doi: 10.1002/pbc.31152. Epub 2024 Jul 2.
3
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.维奈托克和纳武利尤单抗联合化疗治疗复发或难治性急性淋巴细胞白血病和淋巴母细胞淋巴瘤患者。
Cancer Discov. 2021 Jun;11(6):1440-1453. doi: 10.1158/2159-8290.CD-20-1465. Epub 2021 Feb 16.
4
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors.基于 Venetoclax 的挽救疗法治疗既往接受过 FLT3 或 IDH1/2 抑制剂治疗的复发/难治性急性髓系白血病患者。
Leuk Lymphoma. 2023 Jan;64(1):188-196. doi: 10.1080/10428194.2022.2136952. Epub 2022 Oct 26.
5
Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.米托蒽醌、长春新碱、培门冬酶、地塞米松和硼替佐米治疗复发/难治性儿童急性淋巴细胞白血病。
Pediatr Blood Cancer. 2020 Mar;67(3):e28062. doi: 10.1002/pbc.28062. Epub 2019 Nov 14.
6
The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.硼替佐米联合化疗治疗儿童复发/难治性急性淋巴细胞白血病。
Br J Haematol. 2017 Feb;176(4):629-636. doi: 10.1111/bjh.14505. Epub 2017 Jan 24.
7
Venetoclax-based low-intensity chemotherapy in the salvage treatment of relapsed/refractory T-cell acute lymphoblastic leukemia.基于维奈托克的低强度化疗用于复发/难治性T细胞急性淋巴细胞白血病的挽救治疗
Clin Exp Med. 2025 Apr 2;25(1):104. doi: 10.1007/s10238-025-01638-7.
8
Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia.维奈托克和硼替佐米用于复发/难治性早期T细胞前体急性淋巴细胞白血病
JCO Precis Oncol. 2019 Sep 20;3. doi: 10.1200/PO.19.00172. eCollection 2019.
9
Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with pathway alterations.维奈托克在伴有通路改变的成人复发/难治性费城阴性急性淋巴细胞白血病中的持久反应。
Front Cell Dev Biol. 2023 May 23;11:1165308. doi: 10.3389/fcell.2023.1165308. eCollection 2023.
10
A successful case of venetoclax-based therapy in relapsed/refractory secondary plasma cell leukemia.维奈托克治疗复发/难治性继发性浆细胞白血病的成功案例。
J Oncol Pharm Pract. 2020 Jul;26(5):1274-1278. doi: 10.1177/1078155219895072. Epub 2019 Dec 22.

本文引用的文献

1
Salvage treatment in mutated acute lymphoblastic leukemia with venetoclax plus methotrexate and pegaspargase: A case report.维奈托克联合甲氨蝶呤和培门冬酶治疗突变型急性淋巴细胞白血病的挽救治疗：一例报告
Genes Dis. 2023 Mar 24;10(6):2215-2217. doi: 10.1016/j.gendis.2023.02.011. eCollection 2023 Nov.
2
Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia.基于 Venetoclax 的挽救疗法治疗成人复发/难治性急性淋巴细胞白血病。
Eur J Haematol. 2023 Sep;111(3):365-372. doi: 10.1111/ejh.14015. Epub 2023 May 31.
3
The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia.维奈托克为基础的治疗方案在急性淋巴细胞白血病中的新作用。
Int J Mol Sci. 2022 Sep 19;23(18):10957. doi: 10.3390/ijms231810957.
4
Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia.维奈托克和硼替佐米用于复发/难治性早期T细胞前体急性淋巴细胞白血病
JCO Precis Oncol. 2019 Sep 20;3. doi: 10.1200/PO.19.00172. eCollection 2019.
5
The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.硼替佐米联合化疗治疗儿童复发/难治性急性淋巴细胞白血病。
Br J Haematol. 2017 Feb;176(4):629-636. doi: 10.1111/bjh.14505. Epub 2017 Jan 24.